Non-profit
Although the biopharma industry is churning out failure after failure of Alzheimer’s drugs, the start of the Alzheimer’s Association International Conference (AAIC) being held in Chicago this week is being met with optimism.
The UK’s Wellcome Trust, a charitable foundation, announced it is creating the $330 million Leap Fund to invest in high-risk healthcare and life science research.
New York-based Kallyope and Danish company Novo Nordisk A/S signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
The Bill and Melinda Gates Foundation has spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston. Although it found its temporary space in Cambridge, Massachusetts in January, it “officially” launched Thursday at the BIO International Convention in Boston.
The mysterious death of a biotech startup chief executive officer in late April projected the term biohacker into the forefront of the industry lexicon.
The Broad Institute of MIT and Harvard is taking bold steps to acquire samples of every drug ever developed in order to test whether or not they could be used off-label to treat other diseases than the ones for which they were manufactured.
Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
The Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International extended its current collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Bill Gates via The Bill and Melinda Gates Foundation and Google co-founder Larry Page, have pledged $12 million to research to develop a universal flu vaccine. However, they aren’t the only tech billionaires to get into funding healthcare and life science research initiatives.
The 2016 U.S. presidential election was marked by aggressive and often shrill attacks on the biopharma industry over drug pricing.
PRESS RELEASES